Your trusted Partner in End to End Development & Manufacturing of Finished dosage forms.

From formulation to packaging, Synokem delivers world class CDMO services that ensure speed, quality, and compliance — empowering pharma and biotech companies to bring life changing medicines to market faster.

Contract Manufacturing

We are an industry leader in the Contract Development and Manufacturing Organization (CDMO) sector, offering high-quality development and manufacturing services to leading pharmaceutical companies, branded pharma firms, and biotechnology companies.

Our core capabilities include drug formulation development, analytical testing, manufacturing, and packaging, ensuring that our partners can bring their products to market efficiently while meeting all regulatory requirements.

We operate with flexible partnership models, including Product-to-Product (P2P) and Loan License business arrangements, designed to meet the diverse needs of our clients.

Our approach focuses on creating long-term strategic value through strong collaboration, accelerated time-to-market, uncompromised quality standards, and continuous innovation across development, commercialization, product enhancement, and Lifecycle Management (LCM).

KEY FEATURES OF OUR CDMO SERVICES

Product Development & Manufacturing

End-to-end support from formulation development and analytical services to commercial manufacturing and packaging.

Regulatory-Compliant Facilities

Manufacturing operations aligned with global regulatory standards, ensuring consistent quality and compliance.

Advanced Technical Expertise

A team of experienced scientists and professionals with strong capabilities in formulation development, process optimization, and scale-up.

Flexible Manufacturing Capabilities

Ability to support projects from early development stages to large-scale commercial production.

Strong Quality Systems

Robust quality assurance and quality control processes to maintain high standards of product safety, efficacy, and reliability.

Faster Time-to-Market

Efficient project management and streamlined development processes to help partners bring products to market quickly.

Meeting Client Needs

Committed to understanding and fulfilling our clients' needs with precision.

OUR CDMO PRIORITIES

We are sensitive to key success factors that will allow our biotech and pharma partners to succeed in highly competitive markets:

Quality & Excellence

Ensuring the highest standards of quality while maintaining strict compliance with global regulatory guidelines.

Client-Centric

Building long-term partnerships by understanding client needs and delivering customized development and manufacturing solutions.

Innovation & Technical Expertise

Leveraging advanced technologies and scientific expertise to support complex product development and manufacturing.

Operational Efficiency

Continuously improving processes, efficiency, and productivity to ensure reliable and cost-effective services.

First to Launch

Accelerating development timelines and manufacturing processes to help clients bring products to market faster and being market leaders of brands.

Scalability & Flexibility

Providing flexible manufacturing capabilities to support projects from development stages to commercial production.

On time Deliveries

Ensuring reliable on-time delivery to help our partners bring quality pharmaceutical products to market faster.

Cost Competitive

Cost-efficient manufacturing without compromising on quality.

MANUFACTURING CAPABILITIES

We understand the critical success factors that enable our biotech and pharmaceutical partners to thrive in highly competitive markets. These include:

Synokem Pharmaceuticals Ltd. / Synokem Lifesciences Pvt. Ltd.
  • 1. Hormonal Tablets- 60 millions
  • 2. General Tablets- 1 billion
  • 3. Hormonal Capsules- 12 millions
  • 4. General Capsules- 200 millions
  • 5. Cream/Ointment- 2 millions
  • 6. Oral Liquid- 3.10 millions
  • 7. Vaginal Gels- 2 millions
  • ** We will be commencing Sachet Production Soon.
Nitin Lifescience Ltd.
  • 1. Glass Vials- 207 million
  • Dry Powder Injection- 108 million (vials)
  • 2. Glass Ampoules- 420 million
  • 3. Eye/ Ear Drops- 15 million
  • 4. Lyophilized Injection- 31.5 million
  • 5. Cephalosporins Dry Powder- 42 million
  • 6. Beta Lactam- 20 million
  • 7. General Injection- 45 million
Finished Dosage Forms

1. General

  • Tablet
  • Capsules
  • Oral Liquids
  • Ointments
  • Sachets

2. Hormonal

  • Tablet
  • Capsule

3. Injectable

4. Therapeutic Segments